Intelligence / Healthtech / New Clinical Trials / AstraZeneca
Clinicaltrial registered4 Nov 2026
AstraZeneca
4 Nov 2026: Trial registered · Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 4 Nov 2026
- Title
- Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients
- Conditions
- Non-small Cell Lung Cancer, NSCLC, Stage I-II Unresected NSCLC
- Study Type
- Observational
- Status
- Not Yet Recruiting
- Reference
- NCT07914972
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at AstraZeneca
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for AstraZeneca in our registers.
18 NovAstraZenecatrial registered · HealthtechClinical17 NovAstraZenecatrial registered · HealthtechClinical13 NovAstraZenecatrial registered · HealthtechClinical12 NovAstraZenecatrial registered · HealthtechClinical12 NovAstraZenecatrial registered · HealthtechClinical12 NovAstraZenecatrial registered · HealthtechClinical6 NovAstraZenecatrial registered · HealthtechClinical4 NovAstraZenecatrial registered · HealthtechClinical4 NovAstraZenecatrial registered · HealthtechClinical2 NovAstraZenecatrial registered · HealthtechClinical2 NovAstraZenecatrial registered · HealthtechClinical29 OctAstraZenecatrial registered · HealthtechClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.